688302 Hinova Pharmaceuticals Inc.
- 25.37
- -0.55-2.12%
Hinova Pharmaceuticals Inc. News
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Hailansheng Pharmaceutical (688302.SH): a net loss of 0.1 billion yuan in the first half of the year.
Haichuang Pharmaceutical (688302.SH) announced its interim report for the first half of 2024, with revenue of 0.1097 million yuan; net loss attributable to shareholders of listed companies was -0.1 billion yuan, a narrower loss compared to the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was -0.11 billion yuan; basic earnings per share was -1.01 yuan.
HaiChuang Pharmaceutical (688302.SH): The clinical trial of HP560 tablets for the treatment of bone marrow fibrosis has obtained a drug clinical trial approval notice.
On July 24th, Gelunhui announced that Haichuang Pharmaceutical (688302.SH) received the Drug Clinical Trial Approval Notice issued and approved by the Drug Evaluation Center of the China National Medical Products Administration, agreeing to conduct clinical trials of HP560 tablets for the treatment of myelofibrosis. As of the date of this announcement, no similar target product has been approved for listing both domestically and overseas.
Hinova Pharmaceuticals Gets US FDA's Nod to Trial HP537 Tablets
Express News | Hinova Pharma Receives U.S. FDA Study May Proceed Notification for Phase I/II Clinical Trial of HP537 for Treatment of Hematological Malignancies
Hai-Chuang Pharmaceutical (688302.SH) received FDA approval for Phase I/II clinical trials of HP537 tablets for the treatment of hematologic malignancies.
Zhitong Finance APP News, Hicreative Pharmaceutical (688302.SH) announced that the company recently received the Study May Proceed Notification issued by the Food and Drug Administration (FDA), approving the company's clinical phase I/II trial application of HP537 tablets for the treatment of hematologic malignancies. Prior to this, the clinical trial application of HP537 tablets in China had been approved by the National Medical Products Administration (NMPA) in February 2024.
Express News | Hinova Pharmaceuticals Receives FDA Fast Track Designation for HP518 for Treatment of Ar+ Triple-Negative Breast Cancer (Tnbc)
Hai-Chuang Pharmaceutical (688302.SH): Its investigational drug HP518 has received Fast Track Designation from the United States Food and Drug Administration for the treatment of androgen receptor (AR)-positive triple-negative breast cancer.
On June 30th, Gelunhui reported that Haichuang Pharmaceutical Co., Ltd. (688302.SH) recently received "Fast Track Designation" ("FTD") from the US Food and Drug Administration ("FDA") for its HP518 tablets for the treatment of androgen receptor (AR) positive triple-negative breast cancer. Currently, there are no similar targeted products approved for marketing at home or abroad. Previously, HP518 tablets have been used in Australia to treat metastatic castration-resistant prostate cancer.
Hinova Pharmaceuticals (SHSE:688302) Is In A Good Position To Deliver On Growth Plans
Haichuang Pharmaceutical (688302.SH): PROTAC drug under development HP518 will release clinical data at the 2024 American Society of Clinical Oncology Annual Meeting
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that clinical research data on the innovative drug HP518 developed by PROTAC independently developed by the company will be released at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. HP518 is an oral, targeted proteolytic chimera (PROTAC) drug independently developed by the company to treat patients with advanced prostate cancer (mCRPC).
Guo Hong, chief medical officer and core technician of Haichuang Pharmaceutical (688302.SH), left office
Haichuang Pharmaceutical (688302.SH) announced that Guo Hong, the company's chief medical officer and core technical officer, recently due to personal reasons...
Haichuang Pharmaceutical (688302.SH) announced first-quarter results with a net loss of 47.21 million yuan
According to the Zhitong Finance App, Haichuang Pharmaceutical (688302.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved a revenue of 0 yuan; a net profit loss of 47.21 million yuan; and a loss of 52.72 million yuan after deducting non-net profit. Basic earnings per share - $0.48.
Haichuang Pharmaceutical (688302.SH) reported 2023 annual results, unrealized revenue, net loss of 294 million yuan
Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period;...
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%
Haichuang Pharmaceutical (688302.SH): Clinical trial of HP501 extended-release tablets approved
Haichuang Pharmaceutical (688302.SH) issued an announcement. The company received the approval and issuance of “Drugs...” from the State Drug Administration
Haichuang Pharmaceutical (688302.SH) will list and circulate 994,400 restricted shares on April 12, 2024
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that the restricted shares listed and distributed are the company's initial public offering of restricted shares, involving 1 shareholder, CITIC Securities Investment Co., Ltd., an alternative investment subsidiary established by the sponsor in accordance with law. The corresponding number of shares is 994,400 shares, accounting for 1.0002% of the company's total share capital, and will be listed and circulated on April 12, 2024.
Hinova Pharmaceuticals Inc.'s (SHSE:688302) Market Cap up CN¥384m Last Week, Benefiting Both Individual Investors Who Own 41% as Well as Insiders
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets
Haichuang Pharmaceutical (688302.SH): Clinical trial of HP537 tablets to treat hematological malignancies approved
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the State Drug Administration, agreeing to carry out clinical trials with HP537 tablets for “hematological malignancies.” HP537 tablets are mainly used to treat hematologic malignancies, including but not limited to multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (acu)
Analysis
Price Target
No Data
No Data